BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hariri S, Sharafi H, Sheikh M, Merat S, Hashemi F, Azimian F, Tamadoni B, Ramazani R, Gouya MM, Abbasi B, Tashakorian M, Alasvand R, Alavian SM, Poustchi H, Malekzadeh R. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. Harm Reduct J 2020;17:80. [PMID: 33081794 DOI: 10.1186/s12954-020-00431-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Nevens F, Hens N, Robaeys G. Hepatitis C prevalence in incarcerated settings between 2013–2021: a systematic review and meta-analysis. BMC Public Health 2022;22:2159. [DOI: 10.1186/s12889-022-14623-6] [Reference Citation Analysis]
2 Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022;12:e058757. [PMID: 35676019 DOI: 10.1136/bmjopen-2021-058757] [Reference Citation Analysis]
3 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. World J Gastroenterol 2022; 28(14): 1494-1498 [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
4 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. WJG 2022;28:1494-8. [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
5 Richter V, Goldstein L, Cohen DL, Bermont A, Zelnik Yovel D, Madar M, Rabinovitch R, Shirin H, Broide E. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons. Sci Prog 2022;105:368504221105173. [PMID: 35722762 DOI: 10.1177/00368504221105173] [Reference Citation Analysis]
6 Mirzazadeh A, Hosseini-hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M, Khezri M, Mehmandoost S, Shojaei MR, Karamouzian M, Briceno A, Morris MD, Alavian SM, Haghdoost A, Sharifi H, Page KA. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. International Journal of Drug Policy 2022;102:103580. [DOI: 10.1016/j.drugpo.2022.103580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chan HK, Hassali MA, Mohammed NS, Azlan A, Hassan MRA. Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders. BMC Public Health 2022;22:371. [PMID: 35189876 DOI: 10.1186/s12889-022-12786-w] [Reference Citation Analysis]
9 Murphy M, Sosnowy C, Rogers B, Napoleon S, Galipeau D, Scott T, Tao J, Berk J, Clarke J, Nunn A, Chan PA. Defining the Pre-exposure Prophylaxis Care Continuum Among Recently Incarcerated Men at High Risk for HIV Infection: Protocol for a Prospective Cohort Study. JMIR Res Protoc 2022;11:e31928. [PMID: 35142633 DOI: 10.2196/31928] [Reference Citation Analysis]
10 Moradi G, Alavian SM, Gholami F, Ramezani R, Ahangarzadeh L, Moradi Y, Sharafi H. Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019. Pathogens 2021;10:1522. [PMID: 34832678 DOI: 10.3390/pathogens10111522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hariri S, Davari S, Malekzadeh Z, Mohammadi Z, Masoudi S, Gandomkar A, Amini-Kafiabad S, Maghsoudloo M, Merat S, Poustchi H, Malekzadeh F. Prevalence of Hepatitis B and C Infections and Associated Risk Factors in Pars Cohort Study, Southern Iran. Middle East J Dig Dis 2021;13:95-102. [PMID: 34712446 DOI: 10.34172/mejdd.2021.211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Murphy M, Sosnowy C, Rogers B, Napoleon S, Galipeau D, Scott T, Tao J, Berk J, Clarke J, Nunn A, Chan PA. Defining the Pre-exposure Prophylaxis Care Continuum Among Recently Incarcerated Men at High Risk for HIV Infection: Protocol for a Prospective Cohort Study (Preprint).. [DOI: 10.2196/preprints.31928] [Reference Citation Analysis]
13 Hariri S, Alavi M, Roshandel G, Mohammadi Z, Fazel A, Amiriani T, Bazazan A, Motamed-Gorji N, Sohrabpour A, Merat S, Poustchi H, Malekzadeh R. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. Int J Drug Policy 2021;95:103269. [PMID: 33991887 DOI: 10.1016/j.drugpo.2021.103269] [Reference Citation Analysis]
14 Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Rajabi A, Sharafi H, Alavian SM. Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. Harm Reduct J 2021;18:12. [PMID: 33482831 DOI: 10.1186/s12954-020-00441-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]